Reinier de Graaf Groep — Clinical Trial Site

66 Registered trials

28 Currently recruiting

Organisation

Reinier de Graaf Groep

Location

Delft, Netherlands

Identifier

ORG-100042912

Address

Reinier De Graafweg 5, 2625 AD, Netherlands

Departments

#2303: Oncology
#2924:Cardiology
#3722: Cardiology
2304:Medical Oncology
3722: Cardiology
4002: Cardiology
4301: Oncology
Anesthesiology
Anesthesiology and pain
Cardiology
Department of Medical Oncology
gynaecologie
Gynaecology
Hematologie
Hematology
Intensive Care
interne geneeskunde
Medical oncology
Medische Oncologie
N/A
NEK
Neurology
Oncology
Ophthalmology
Reinier de Graaf Gasthuis, dept. Internal medicine
Reproductive medicine and gynecology
Research cardiologie
Research cardiology
Research department Cardiology
Research Unit Oncology
Surgery
Urology

Clinical trials at this site (66)

Search interface

VulVaccin study Recruiting

2023-506792-94-00 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSI 11 2024-03-04
EASYlight study Recruiting

2023-508417-16-00 Endometriosis 6 2024-02-14
Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting

2023-508389-13-00 Combined endpoint of all-cause mortality, kidney failur 5 2022-11-08
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting

2023-503442-30-00 Multiple Myeloma 5 2022-10-14
The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2… Recruiting

2024-513797-22-00 HER2 positive esophageal adenocarcinoma 5 2022-03-09
Treatment of chronic lymphocytic leukaemia with venetoclax and acalabrutinib in case of return of the disease after previous treatment with … Recruiting

2023-505449-18-00 Patients with relapsed CLL 4 2020-07-23
DRUP trial Recruiting

2023-509152-33-00 Advanced solid tumor 4 2016-07-25
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
Multi-institutional Evaluation of the Cost-effectiveness of PSMA-PET/CT for the Detection of Pelvic Lymph Node Invasion in Newly Diagnosed P… Ended

2024-518171-59-00 Prostate Cancer 11 2025-01-23
A Patient guided dose reduction strategy of tyrosine kinase inhibitors in chronic myeloid leukaemia: RODEO study Ended

2024-516511-24-00 Chronic myeloid leukaemia 11 2024-11-14
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing pep… Ended

2023-506717-21-00 Breast Cancer 9 2024-10-02
MAD Ended

2024-516379-34-00 Myopia 6 2024-08-02
Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended

2024-513105-31-00 Multiple Sclerosis 6 2024-07-30
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended

2022-502664-21-00 multiple sclerosis 6 2023-05-01
Does progesterone luteal phase support increase live birth rates in couples undergoing intra-uterine insemination with Mild Ovarian HyperSti… Ended

2022-501534-33-00 Unexplained Subfertility, infertility 6 2023-03-06
SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat… Ended

2024-514965-20-00 Breast cancer 4 2022-06-02
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
Personalized dosing of ocrelizumab in MS Ended

2024-513193-22-00 Multiple Sclerosis 11 2022-03-16
An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended

2023-507970-42-00 PSMA-positive metastatic hormone-sensitive prostate can 5 2021-03-31